Industry Unity May Not Solve Pharma’s PR Problems, Tobacco Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Speaking as a single industry stifles innovation and can lead to criticism of an entire industry because of one company’s problems, Altria Group VP says at The Economist roundtable in Philadelphia.
You may also be interested in...
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states
Risk Management Guidance Suggests Using Claims Data To Evaluate Safety Signals
Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.